05:03 AM EDT, 07/29/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) said Sunday that sabirnetug lowered the levels of cerebrospinal fluid, or CSF, in a phase 1 trial for the treatment of Alzheimer's disease, a result that was "consistent" with the therapy's proposed mechanism of action.

"VAMP2, a biomarker associated with synaptic injury, was significantly lowered in all multiple ascending dose cohorts and appeared to be the biomarker most sensitive to sabirnetug in this study," the company said.

Acumen plans to assess longer-term changes in biomarkers and their relationship to clinical outcomes in an ongoing phase 2 trial of sabirnetug.

Price: 3.5097, Change: +0.03, Percent Change: +0.85